STERV:OMXHEXStora Enso Oyj Class R Analysis
Data as of 2026-03-11 - not real-time
€10.55
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Stora Enso’s share price sits at €10.55, comfortably above the computed support of €10.26 and below the resistance of €12.26, with the 20‑day SMA (€11.13) perched above both the 50‑day (€10.79) and 200‑day (€9.85) averages, signaling a bullish backdrop. RSI at 42.8 suggests the stock is not yet oversold nor overbought, while the MACD histogram is negative and the signal line is bearish, hinting at short‑term momentum weakness. Volume is on an increasing trend and the 30‑day volatility is high at 41%, reflecting active trading. Recent material news confirms a profit beat, a planned bond redemption of €500 million, and an upcoming AGM, all of which provide a positive catalyst backdrop.
Fundamentally, the stock trades at a forward PE of ~12 and a price‑to‑book of 0.77, with a dividend yield of 2.35% and a modest payout ratio of 28%, supporting dividend sustainability. The DCF‑derived fair value of €3.81 is far below the market price, yet analyst targets (median €12) and a 12.5% upside estimate suggest the market may be undervaluing the company relative to peers. Low beta (~0.19) indicates limited systematic risk, but high volatility and a “Greed” sentiment score (74.8) add caution. Overall, the blend of bullish technical positioning, solid dividend profile, and attractive valuation relative to analyst expectations makes the stock appealing for medium‑ to long‑term investors.
Fundamentally, the stock trades at a forward PE of ~12 and a price‑to‑book of 0.77, with a dividend yield of 2.35% and a modest payout ratio of 28%, supporting dividend sustainability. The DCF‑derived fair value of €3.81 is far below the market price, yet analyst targets (median €12) and a 12.5% upside estimate suggest the market may be undervaluing the company relative to peers. Low beta (~0.19) indicates limited systematic risk, but high volatility and a “Greed” sentiment score (74.8) add caution. Overall, the blend of bullish technical positioning, solid dividend profile, and attractive valuation relative to analyst expectations makes the stock appealing for medium‑ to long‑term investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above key support with bullish SMA hierarchy
- Bearish MACD signal indicating possible pull‑back
- Increasing volume supporting price stability
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Analyst median target of €12 exceeds current price
- Solid dividend yield and low payout ratio
- Profit beat and bond redemption improving balance‑sheet perception
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustainable renewable business model in packaging and biomaterials
- Low beta and defensive dividend profile
- Long‑term upside potential indicated by upside/downside estimate and sector fundamentals
Key Metrics & Analysis
Financial Health
Revenue Growth-2.90%
Profit Margin7.45%
P/E Ratio12.0
ROE6.65%
ROA0.75%
Debt/Equity42.01
P/B Ratio0.8
Op. Cash Flow€645.0M
Free Cash Flow€-297875008
Technical Analysis
TrendBullish
RSI42.8
Support€10.26
Resistance€12.26
MA 20€11.13
MA 50€10.79
MA 200€9.85
MACDBearish
VolumeIncreasing
Fear & Greed Index74.79
Valuation
Fair Value€3.81
Target Price€11.88
Upside/Downside12.56%
GradeUndervalued
TypeValue
Dividend Yield2.35%
Risk Assessment
Beta0.19
Volatility41.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.